Fig. 2From: Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemiaEchocardiogram after four doses of gilteritinib demonstrating acutely reduced systolic function and global hypokinesis. After four doses of gilteritinib targeted therapy, an echocardiogram showed moderately reduced left ventricular systolic function, an estimated ejection fraction of 36% with global hypokinesis and regional abnormalities of the septumBack to article page